patient subgroup...
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
la/mBC - HER2 positive - 2nd Line (L2), neratinib based treatment versus lapatinib plus capecitabine, meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.88 [0.74, 1.06]< 1 0% 2 studies (2/-) 91.2 % some concern not evaluable moderate crucial - progression or deaths (PFS) 0.74 [0.62, 0.89]< 1 0% 2 studies (2/-) 99.9 % some concern not evaluable moderate important - DOR 0.50 [0.34, 0.73]< 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate non important - objective responses (ORR) 1.02 [0.37, 2.80]> 1 0% 1 study (1/-) 51.4 % NA not evaluable non important - AE (grade 3-4) endpoints 00 Anaemia AE (grade 3-4) 0.48 [0.02, 14.79]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - Asthenia AE (grade 3-4) 0.31 [0.03, 3.12]< 1 0% 1 study (1/-) 83.7 % NA not evaluable non important - Back pain AE (grade 3-4) 0.98 [0.02, 50.38]< 1 0% 1 study (1/-) 50.4 % NA not evaluable non important - Constipation AE (grade 3-4) 0.98 [0.02, 50.38]< 1 0% 1 study (1/-) 50.4 % NA not evaluable non important - Decreased appetite AE (grade 3-4) 0.98 [0.06, 16.11]< 1 0% 1 study (1/-) 50.6 % NA not evaluable non important - Diarrhoea AE (grade 3-4) 2.48 [0.79, 7.77]< 1 0% 1 study (1/-) 6.0 % NA not evaluable non important - Fatigue AE (grade 3-4) 0.98 [0.13, 7.24]< 1 0% 1 study (1/-) 50.8 % NA not evaluable non important - Headache AE (grade 3-4) 0.98 [0.02, 50.38]< 1 0% 1 study (1/-) 50.4 % NA not evaluable non important - Nausea AE (grade 3-4) 0.64 [0.10, 4.00]< 1 0% 1 study (1/-) 68.3 % NA not evaluable non important - Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4) 0.98 [0.29, 3.27]< 1 0% 1 study (1/-) 51.5 % NA not evaluable non important - Pyrexia AE (grade 3-4) 0.48 [0.02, 14.79]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - Rash AE (grade 3-4) 0.48 [0.02, 14.79]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - Stomatitis AE (grade 3-4) 0.48 [0.02, 14.79]< 1 0% 1 study (1/-) 65.9 % NA not evaluable non important - Vomiting AE (grade 3-4) 0.98 [0.06, 16.11]< 1 0% 1 study (1/-) 50.6 % NA not evaluable non important - Weight decreased AE (grade 3-4) 0.98 [0.06, 16.11]< 1 0% 1 study (1/-) 50.6 % NA not evaluable non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.